Oxytocin
Hormone approved in obstetrics, used off-label in social cognition
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Small peptide hormone produced in the brain and released by the pituitary. In medicine it is an approved drug, by IV or IM route, for labor induction, control of postpartum bleeding and lactation. Intranasal use in social cognition and bonding is off-label and single-dose in most studies.
Quick reference
- Route
- IV/IM approved in obstetrics. Intranasal (10–72 IU) and SC (100–500 mcg) are research contexts.
- Measure
- 1 IU ≈ 2 mcg of pure peptide. A 2 mg vial ≈ 1,000 IU; a 5 mg vial ≈ 2,500 IU.
- Bioavailability
- Intranasal sits around 1–2%. Subcutaneous does not cross the blood–brain barrier to any relevant degree.
- Evidence
- Strong for obstetric IV use. Mixed and mostly negative for social outcomes in autism, after SOARS-B (NEJM 2021).
Oxytocin research protocol formats
| Trial Context | Per-session dose | Frequency in trial |
|---|---|---|
| Single-dose social-cognition studies | 24 IU | 1x |
| Dose-response brain imaging | 9, 18, or 36 IU | 1x |
| SOARS-B autism RCT (Sikich 2021) | Up to 48 IU/day total | split 2×/day |
| Adult ASD trials (Anagnostou 2012, others) | 24-48 IU/day total | split 2×/day |
Oxytocin research protocol formats
| Range | Per-dose amount | Frequency seen in protocols |
|---|---|---|
| Low | 100 mcg | 1×/day |
| Moderate | 200-300 mcg | 1×/day |
| Upper | 400-500 mcg | 1×/day |
Oxytocin Timeline & What to Monitor
| Endpoint | Study type | Timing |
|---|---|---|
| Plasma peak after IV | PK study | Within minutes |
| Plasma peak after intranasal | PK study | ~15-30 minutes |
| CSF detection after intranasal | Primate / human PK | Within 30-75 minutes (limited data) |
| Social-cognition behavioral endpoints | Acute RCT | 30-90 minutes post-dose |
| Longer-term symptom endpoints (autism) | Phase 2 RCT (SOARS-B) | 12-24 weeks of treatment |
Oxytocin vs Pitocin vs Syntocinon vs Kisspeptin
| Name | What it is | Notes |
|---|---|---|
| Oxytocin | Endogenous peptide hormone; synthesized for clinical use | FDA-approved (IV/IM) obstetric drug; investigational for other routes. |
| Pitocin | US brand name for synthetic oxytocin injection | Same molecule as oxytocin USP. |
| Syntocinon | International brand name for synthetic oxytocin | Was marketed as intranasal milk let-down spray; mostly discontinued. |
| Carbetocin | Long-acting oxytocin analog (Duratocin/Pabal) | Approved in many countries for postpartum hemorrhage; not FDA-approved in the US. |
| Vasopressin (AVP) | Sister neurohypophysial peptide, differs from oxytocin by 2 amino acids | Different receptor (V1a/V1b/V2); fluid balance and stress role, not labor or social cognition. |
| Kisspeptin | Separate hypothalamic peptide | Linked to GnRH/reproductive axis; sometimes studied in behavioral neuroscience but a different system. |
| PT-141 (Bremelanotide) | Melanocortin receptor agonist | Not an oxytocin analog; sometimes paired with oxytocin in community sexual-function research but pharmacologically distinct. |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.